Home 
Scientific Publications 2010 Chagas
Scientific Publications 2010 Chagas
Scientific Publications-2010-Chagas
2010
Nature Outlook Chagas Disease supplement. Nature Supplement, 2010 June, Vol. 465, No. 7301 suppl. ppS3-S22
Chagas disease is one of the most neglected of the tropical diseases, yet millions of people are infected with it. There are only two available drugs to treat it, both of which are more than 40 years old and neither of which is ideal. As the global population has become more internationally mobile, Chagas disease has spread from Latin America to become a worldwide threat. This Outlook highlights some of the progress in understanding and treating Chagas disease over its 101 years of recent history and outlines the challenges still to be met.
In vitro and in vivo experimental models for drug screening and development for Chagas disease by Romanha A J, de Castro S L, de Nazaré Correia Soeiro M, Lannes-Vieira Ribeiro I, Talvani A, Bourdin B, Blum B, Olivieri B, Zani C, Spadafora C, Chiari E, Chatelain E, Chaves G, Calzada J E, Bustamante J M, Freitas-Junior L H, Romero L I, Bahia M T, Lotrowska M, Soares M, Andrade S G, Armstrong T, Degrave W, de Araújo Andrade Z. Mem Inst Oswaldo Cruz, 2010 March, Vol. 105 (2): 233-238
Although the occurrence of acute cases of Chagas disease has declined, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been assayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of a workshop held in Rio de Janeiro, Brazil, in November 2008: the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.
Click here to read the article
Nature Outlook Chagas Disease supplement. Nature Supplement, 2010 June, Vol. 465, No. 7301 suppl. ppS3-S22Chagas disease is one of the most neglected of the tropical diseases, yet millions of people are infected with it. There are only two available drugs to treat it, both of which are more than 40 years old and neither of which is ideal. As the global population has become more internationally mobile, Chagas disease has spread from Latin America to become a worldwide threat. This Outlook highlights some of the progress in understanding and treating Chagas disease over its 101 years of recent history and outlines the challenges still to be met.
In vitro and in vivo experimental models for drug screening and development for Chagas disease by Romanha A J, de Castro S L, de Nazaré Correia Soeiro M, Lannes-Vieira Ribeiro I, Talvani A, Bourdin B, Blum B, Olivieri B, Zani C, Spadafora C, Chiari E, Chatelain E, Chaves G, Calzada J E, Bustamante J M, Freitas-Junior L H, Romero L I, Bahia M T, Lotrowska M, Soares M, Andrade S G, Armstrong T, Degrave W, de Araújo Andrade Z. Mem Inst Oswaldo Cruz, 2010 March, Vol. 105 (2): 233-238Although the occurrence of acute cases of Chagas disease has declined, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been assayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of a workshop held in Rio de Janeiro, Brazil, in November 2008: the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.
Click here to read the article
Scientific Publications
Except where otherwise noted, content on this site is licensed under
a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License